切换导航
About Us
Our Story
Our Mission
History
Global Footprint
Leadership
Board of Directors
Science & Technology
Pipeline
Collaborations
CDMO Services
About CDMO
Strength
Services Offered
Learn More
Investors & Media
Join Us
EN
中文
Home
>
Investors & Media
Investors & Media
Immorna has successfully closed 3 rounds of financing with a total of 8 investors, including leading venture capitals and industry investors.
We welcome new investors. For investment
opportunities, please contact
ir@immornabio.com
News Flow
News Update
Immorna Biotherapeutics Announces First Clinical Administration of JCXH-213, a Breakthrough mRNA-based In Vivo CAR Therapy
ImmornaBiotherapeutics today announced the successful dosing of the first patient in itsclinical stu...
View More
2025.03
News Update
Immorna Receives Grant from Bill & Melinda Gates Foundation to Support Its mRNA RSV Vaccine Clinical Development
Research Triangle Park, NC Aug 14, 2024 – Immorna Biotherapeutics Inc. (Immorna) today announces tha...
View More
2024.08
News Update
Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors
MORRISVILLE, N.C., July 8, 2024 /PRNewswire/ -- ImmornaBiotherapeutics, Inc. (Immorna), a clinical s...
View More
2024.07
News Update
Immorna Biotherapeutics Presents Clinical Data for JCXH-211, a Self-Replicating RNA Encoding the Human IL-12, at ASCO 2024
Immorna Biotherapeutics PresentsClinical Data for JCXH-211, a Self-Replicating RNA Encoding the Huma...
View More
2024.06
News Update
Immorna Announces First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles
MORRISVILLE, N.C., May 30, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company f...
View More
2023.05
News Update
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine
MORRISVILLE, N.C., January 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology compan...
View More
2023.01
More